Angiotensin-converting enzyme (ACE) inhibitors modulate the function of the renin-angiotensin-aldosterone system, and they are commonly prescribed antihypertensive drugs especially in patients with renal failure. In this study, the relationships between several molecular properties of eight ACE inhibitors (enalapril, quinapril, fosinopril, ramipril, benazepril, perindopril, moexipril, trandolapril) and their renal elimination data, from relevant literature, were investigated. The ’molecular descriptors of the ACE inhibitors, which included aqueous solubility data (logS); an electronic descriptor, polar surface area (PSA);, a constitutional parameter, molecular mass (Mr); and a geometric descriptor, volume value (Vol), as well as lipophilicity descriptors (logP values), were calculated using different software packages. Simple linear regression analysis showed the best correlation between renal elimination data and lipophilicity descriptor AClogP values (R2 = 0.5742). In the next stage of the study, multiple linear regression was applied to assess a higher correlation between the ACE inhibitors’ renal elimination data and lipophilicity, AClogP, with one additional descriptor as an independent variable. Good correlations were established between renal elimination data from the literature and the AClogP lipophilicity descriptor using the constitutional parameter (molecular mass (R2 = 0.7425)) or the geometric descriptor (volume value (R2 = 0.7224)) as an independent variable. The application of computed molecular descriptors in evaluating drug elimination is of great importance in drug research.
1. Lemke TL, Williams DA (eds). The Foye’s Principles of Medicinal Chemistry 6 th ed. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, 2013.
2. Giverhaug T, Falck A, Eriksen BO. Effectiveness of anti-hypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure? J Hum Hypertens 2004; 18: 649-54.
3. Piepho RW. Overview of the angiotensin-convering-enzime inhibitors. Am J HealthSystem Pharm 2000; 57: 3-7.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Farmacology 8 th, Elsevier, Churchill Livingstone, 2012.
5. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.
6. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin converting enzyme inhibitor. Am J Cardiol 1995; 75: 7F-12F.
7. Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hipertens 1991; 2: 23S-28S.
8. Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. Am J Hiperten 1995; 8: 63S-67S.
9. Conen H, Brunner HR. Pharmacologic profile of trandolapril a new angiotensin converting enzyme inhibitor. Am Hearth J 1993; 125: 1525-1531.
10. Ranadive SA, Chen AX, Serajuddin TM. Relative lipophilicities and structural – pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Research 1992; 9: 1480-1486. 12
11. Abbara Ch, Aymard G, Hinh S, Diquet B. Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 2002; 766: 199-207.
12. Gumieniczek A, Hopkala H. High performance chromatographic assay of quinapril in tablets. Pharm Acta Helv 1998; 73: 183-185.
14. El-Gindy A, Ashour A, Fattah LA, Shabana MM. Spectrophotometric and HPTLC densitometric determination of lisinopril and hydrochlorothiazide in binary mixtures. J Pharm Biomed Anal 2001; 25: 923-931.
15. Prieto JA, Akesolo U, Jimenez RM, Alonso RM. Capillary zone electrophoresis applied to the determination of the angiotensin-converting enzyme inhibitor cilazapril and its active metabolite in pharmaceuticals and urine. J Chromatogr A 2001; 916: 279-288.
16. El-Gindy A, Ashour A, Abdel Fattah L, Shabana MM. Spectrophotometric, spectrofluorimetric and LC determination of lisinopril. J Pharm Biomed Anal 2001; 25: 913-922.
17. Bonazzi D, Gotti R, Andrisano V, Cavrini V. Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC) J Pharm Biomed Anal 1997; 16: 431-438.
18. Odovic JV, Stojimirovic BB, Aleksic MB, Milojković-Opsenica DM, Tešic Ž.Lj. Examination of the hydrophobicity of ACE inhibitors and their active metabolites by salting-out thin-layer chromatography. J Planar Chromat 2005; 18: 98-103. 13
19. Odovic J, Stojimirovic B, Aleksic M, Milojkovic-Opsenica D, Tesic Z. Reversedphase thin-layer chromatography of some angiotensin converting enzyme (ACE) inhibitors and their active metabolites. J Serb Chem Soc 2006; 71(6): 621-628.
20. Odovic J, Aleksic M, Stojimirovic B, Milojkovic-Opsenica D, Tesic Z. Normal-phase thin-layer chromatography of some ACE inhibitors and their metabolites. J Serb Chem Soc 2009; 74(6): 677-688.
21. Odovic J, Trbojevic-Stankovic J. Correlation between Angiotensin-converting enzyme inhibitors lipophilicity and protein binding data. Acta Medica Medianae 2012; 51(4): 13-18.
22. Odovic JV, Markovic, BD, Injac RD, Vladimirov SM Karljikovic-Rajic KD. Correlation between ultra-high performance liquid chromatography–tandem mass spectrometry and reversed-phase thin-layer chromatography hydrophobicity data for evaluation of angiotensin-converting enzyme inhibitors absorption. J Chromatogr A 2012; 1258: 94-100.
23. Molinspiration software or free molecular property calculation services. Available from URL: www.molinspiration.com
24. Tetko IV. Virtual Computational Chemistry Laboratory. Available from URL: www.vcclab.org
26. Di L, Kernsy EH. Profiling drug - like properties in discovery research. Curr Opin Chem Biol 2003; 7:402-408.
27. Remko M, Swart M, Matthias Bickelhaupt F. Theoretical study of structure, pKa, lipophilicity, solubility, absorption and polar surface area of some centrally acting antihypertensives. Bioorg Med Chem 2006; 14: 1715-1728. 14
28. Remko M. Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chem Pap 2007; 61(2): 133-141.
29. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherbone B, Cooper I, Platts JA. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 2001; 90: 749-784.
30. Hellstern A, Hildebrand M, Humpel M, Hellenbrecht D, Saller R, Madetzki C. Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. Int J Clin Pharmacol Ther Toxicol 1990; 28(6): 256–261.
31. Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev 2003; 35(4): 305–317.
32. Verho M, Luck C, Stelter WJ, Rangoonwala B, Bender N. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin 1995; 13(5): 264–273.
33. Ghose AK, Viswanadhan VN, Wendoloski JJ. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. J Combin Chem 1999; 1: 55–68.
34. Asuero AG, Sayago A, Gonzalez AG. The correlation coefficient: An overview. Crit Rev Anal Chem 2006; 36: 41-59